<DOC>
	<DOCNO>NCT00673816</DOCNO>
	<brief_summary>This open-label study pilot use systemic sunitinib malate , dual inhibitor vascular endothelial growth factor ( VEGF ) platelet derive growth factor ( PDGF ) , five participant Von Hippel-Lindau ( VHL ) investigate potential efficacy treatment retinal angioma . Participants visual dysfunction either visual acuity loss visual field loss retinal angioma secondary genetically confirm VHL . This open-label study pilot use systemic sunitinib malate five participant investigate potential efficacy treatment retinal angioma associate VHL . Participants receive nine month sunitinib malate therapy ( six cycle total - one cycle consist 50 mg oral dose daily four week follow two week rest period ) . The primary outcome change best-corrected visual acuity equal 15 letter baseline Week 36 visit . The secondary ocular outcome focus retinal thickness leakage retinal angioma Week 36 visit . Optical coherence tomography document change retinal thicken fluorescein angiography use determine leakage retinal angioma .</brief_summary>
	<brief_title>Sunitinib Malate Treat Advanced Eye Disease Patients With Von Hippel-Lindau Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Participant must understand sign inform consent . 2 . Participant must least 18 year age . 3 . Participant must genetically confirm VHL disease . 4 . Participant must optic nerve angioma secondary VHL one eye . 5 . Participant must optic nerve tumor cause visual field depression microperimetry1 correlate retinal angioma OR participant clinically may hard exudate correlate retinal angioma OR bestcorrected visual acuity 20/40 worse study eye . 6 . Participant must clear ocular medium adequate pupillary dilation permit good quality stereoscopic fundus photography . 7 . All woman childbearing potential must negative urine pregnancy test baseline , regular negative pregnancy test take sunitinib malate . ( Sunitinib malate potential teratogenic abortifacient effect , data regard safety pregnant woman available ) . 8 . All woman childbearing potential sexually active men sexually active require use two form birth control course study . 9 . Participants must normal organ marrow function define : WBC count ≥ 3,000/µL , absolute neutrophil count ≥ 1,500/µL , platelet count ≥ 100,000/µL , HGB &gt; 10g/dl , serum creatinine ≤ 2.0 measure 24 hr . creatinine clearance &gt; 50 ml/min , AST ALT &lt; 2.5 x ULN , total bilirubin ≤ ULN ( &lt; 3 x NL participants Gilbert 's disease ) . 10 . Participant must negative HbsAg nonreactive HCV . 11 . Participant must negative HIV1 , potential pharmacokinetic interaction drug use treat HIV , antiretroviral drug , sunitinib malate unknown . 12 . Participant must least four week completion investigational therapy VHL . 13 . Participant must ECOG performance score 02 . ( See Appendix 3 ECOG Performance Criteria ) . 14 . Participant recover acute toxicity prior treatment VHL . Exclusion Criteria 1 . Participant history ( within past five year ) evidence severe cardiac disease include heart failure meet New York Heart Association ( NYHA ) class III IV definition , uncontrolled dysrhythmias , dysrhythmias require antiarhythmic drug active ischemic heart disease include myocardial infarction poorly control angina within 12 month study entry . 2 . Participant history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation , ≥ three beat row ) leave ventricular ejection fraction ≤ 40 % . 3 . Participant history serious intercurrent medical illness . 4 . Participant transient ischemic attack cerebrovascular accident within 12 month study entry . 5 . Participant hypertension control medication ( persistent elevation systolic BP &gt; 150 diastolic BP &gt; 100 mmHg despite optimal medical therapy ) . 6 . Participant therapeutic anticoagulation , include aspirin . 7 . Participant breastfeeding , unknown potential risk adverse event nurse infant secondary treatment mother sunitinib malate . 8 . Participant received major surgical procedure within one month study entry surgical scar heal . 9 . Participant know serious allergy fluorescein dye . 10 . Participant currently take drug ingest food affect sunitinib malate plasma concentration : strong inhibitor CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , grapefruit juice ) and/or inducer CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort ) . 11 . Participant prior concomitant nonVHLassociated malignancy exception adequately treat basal squamous cell carcinoma skin malignancy patient remain disease free five year . 12 . Participant chemotherapy radiotherapy within four week ( six week nitrosoureas mitomycin C ) prior enter study recover adverse event ( Grade 1 less toxicity accord CTCAE 3.0 ) due agent administer four week earlier . 13 . Participant receive investigational agent . 14 . Participants know brain metastasis ( except adequately control , i.e. , grown size , ≥ 6 month enrollment ) , include hemangioblastoma , know VHL complication brain . 15 . Participant know bleed disorder . 16 . Participant currently take sunitinib malate take sunitinib malate past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Von Hippel Lindau</keyword>
	<keyword>Sunitinib Malate</keyword>
	<keyword>Sutent</keyword>
	<keyword>Von Hippel-Lindau Syndrome</keyword>
	<keyword>VHL</keyword>
</DOC>